MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fechado

3.71 -2.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.67

Máximo

3.71

Indicadores-chave

By Trading Economics

Rendimento

44M

-26M

Vendas

-5.8M

42M

Margem de lucro

-61.388

Funcionários

550

EBITDA

44M

-22M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+14.56% upside

Dividendos

By Dow Jones

Próximos Ganhos

17 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

360M

1.4B

Abertura anterior

6.59

Fecho anterior

3.71

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de jan. de 2026, 18:41 UTC

Ganhos

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de jan. de 2026, 09:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

24 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

24 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

24 de jan. de 2026, 06:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 de jan. de 2026, 22:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de jan. de 2026, 22:30 UTC

Conversa de Mercado

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 de jan. de 2026, 22:03 UTC

Ganhos

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 de jan. de 2026, 21:52 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

23 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

23 de jan. de 2026, 21:39 UTC

Ganhos

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 de jan. de 2026, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 de jan. de 2026, 21:12 UTC

Ganhos

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 de jan. de 2026, 20:31 UTC

Ganhos

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 de jan. de 2026, 20:12 UTC

Conversa de Mercado

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 de jan. de 2026, 20:07 UTC

Conversa de Mercado

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 de jan. de 2026, 19:36 UTC

Conversa de Mercado

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 de jan. de 2026, 19:30 UTC

Conversa de Mercado
Ganhos

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 de jan. de 2026, 19:18 UTC

Conversa de Mercado

Gold and Silver Step Up to More Records -- Market Talk

23 de jan. de 2026, 19:15 UTC

Ganhos

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23 de jan. de 2026, 18:53 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23 de jan. de 2026, 18:21 UTC

Ganhos

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23 de jan. de 2026, 18:19 UTC

Conversa de Mercado

Intel Seen as Increasingly Confident on Demand -- Market Talk

23 de jan. de 2026, 17:59 UTC

Ganhos

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23 de jan. de 2026, 17:57 UTC

Conversa de Mercado

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23 de jan. de 2026, 17:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Maravai LifeSciences Holdings Inc (Class A) Previsão

Preço-alvo

By TipRanks

14.56% parte superior

Previsão para 12 meses

Média 4.25 USD  14.56%

Máximo 4.5 USD

Mínimo 4 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Maravai LifeSciences Holdings Inc (Class A) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

3

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.02 / 2.115Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat